Table 2 Phase III trials of bevacizumab in combination with chemotherapy in metastatic breast cancer
Reference | Number of patients | Therapy | ORR (%) | PFS (months) |
|---|---|---|---|---|
Miller et al. [19] | 232 | B (15 mg/kg q3w) + capecitabine | 20 (previous anthracycline and taxane) | 5 (TTP) |
| Â | 230 | Capecitabine | 9 (P = 0.001) | 4 |
Miller et al. [20] (E2100) | 368 (347 intent-to-treat) | B (10 mg/kg q2w) + paclitaxel | 37 (1st line) | 12 (TTP) |
| Â | 354 (326 intent-to-treat) | Paclitaxel | 21 | 6 (P < 0.001) |
Miles et al. [21] (AVADO) | 248 | B (7.5 mg/kg q3w) + docetaxel | 55 (1st line) | 9 (P = 0.045) |
| Â | 247 | B (15 mg/kg q3w) + docetaxel | 64 | 10 (P < 0.001) |
| Â | 241 | Placebo + docetaxel | 46 | 8 |
Robert et al. [22] (RIBBON-1) | 409 | B (15mg/kg q3w) + capecitabine | 35 (1st line) | 10 (P = 0.0011) |
| Â | 206 | Capecitabine | 24 | 6 |
| Â | 415 | B (15 mg/kg q3w) + taxane or anthracycline-based therapy | 51 | 11 (P = 0.040) |
| Â | 207 | Taxane or anthracycline-based therapy | 38 | 8 |
684 | B + chemotherapy (capecitabine, gemcitabine, vinorelbine) | 40 (2nd line) | 7 (P = 0.0072) | |
| Â | Â | Chemotherapy | 30 | 5 |